ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 1.7.2 (20 November 2019) - 2999001/03365679CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120210310W154 72deBibliographieenBibliographyfrBibliographieEP16785139.32016102120180517enenen1500303920151023EP2021031020211020180829201835202012302020532020081320210310202110G01N 33/574 20060101AFI20170509BHEP deVERFAHREN ZUR IDENTIFIKATION EINER EINZELPERSON DAHINGEHEND, DASS SIE DURCH CHEMOTHERAPIE ZU BEHANDELN IST, AUF BASIS VON MARKERMOLEKÜLEN UND VERWANDTE VERWENDUNGENenMETHODS OF IDENTIFYING AN INDIVIDUAL AS TO BE TREATED BY CHEMOTHERAPY BASED ON MARKER MOLECULES AND RELATED USESfrPROCÉDÉS D'IDENTIFICATION D'UN INDIVIDU DEVANT ÊTRE TRAITÉ PAR CHIMIOTHÉRAPIE EN SE BASANT SUR DES MOLÉCULES DE MARQUEURS ET UTILISATIONS ASSOCIÉESMULEY TH ET AL: "50: Do preoperatively elevated CYFRA 21-1 or CEA values qualify for adjuvant chemotherapy in completely resected stage I NSCLC patients?", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT; 12TH INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR; HAMBURG, GERMANY, vol. 23, no. 6B, 1 November 2003 (2003-11-01), page 4507, XP008179384, ISSN: 0250-7005MULEY T ET AL: "Increased CYFRA 21-1 and CEA Levels are Negative Predictors of Outcome in p-Stage I NSCLC", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 5B, 1 September 2003 (2003-09-01), pages 4085-4093, XP008153792, ISSN: 0250-7005TAKESHI HANAGIRI ET AL: "Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 1, 6 February 2011 (2011-02-06), pages 112-117, XP028288128, ISSN: 0169-5002, DOI: 10.1016/J.LUNGCAN.2011.02.001 [retrieved on 2011-02-22]MULEY T ET AL: "Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 60, no. 3, 1 June 2008 (2008-06-01), pages 408-415, XP022691011, ISSN: 0169-5002, DOI: 10.1016/J.LUNGCAN.2007.10.026 [retrieved on 2008-02-20]Jan Kulpa ET AL: "Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients", Clinical Chemistry, 1 November 2002 (2002-11-01), pages 1931-1937, XP055257310, United States Retrieved from the Internet: URL:http://www.clinchem.org/content/48/11/ 1931.full.pdf [retrieved on 2016-03-10]BLANKENBURG FLORIAN ET AL: "Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score", TUMOUR BIOLOGY : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE, INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE, SWITZERLAND, vol. 29, no. 4, 1 January 2008 (2008-01-01), pages 272-277, XP008179382, ISSN: 1423-0380, DOI: 10.1159/000152945 [retrieved on 2008-09-09]EBERT W ET AL: "Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study", EUROPEAN JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, WALTER DE GRUYTER, BERLIN, DE, vol. 32, no. 3, 1 March 1994 (1994-03-01), pages 189-199, XP008179383, ISSN: 0939-4974, DOI: 10.1515/CCLM.1994.32.3.189 [retrieved on 2009-09-16]Macmillan ET AL: "Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1", Br. J. Cancer, 1 January 1994 (1994-01-01), pages 525-528, XP055257295, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl es/PMC1968860/pdf/brjcancer00193-0119.pdf [retrieved on 2016-03-21]D. MORO ET AL: "CEA, CYFRA21-1 and SCC in non-small cell lung cancer", LUNG CANCER., vol. 13, no. 2, 1 October 1995 (1995-10-01), pages 169-176, XP055257391, NL ISSN: 0169-5002, DOI: 10.1016/0169-5002(95)00485-8WIESKOPF B ET AL: "Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role", CHEST, AMERICAN COLLEGE OF CHEST PHYSICIANS, US, vol. 108, no. 1, 1 July 1995 (1995-07-01), pages 163-169, XP002448261, ISSN: 0012-3692M Plebani ET AL: "Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?", , 1 January 1995 (1995-01-01), pages 170-173, XP055257408, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl es/PMC2034156/pdf/brjcancer00041-0174.pdf [retrieved on 2016-03-10]YOSHIKI KOZU ET AL: "Prognostic significance of postoperative serum carcinoembryonic antigen levels in patients with completely resected pathological-stage I non-small cell lung cancer", JOURNAL OF CARDIOTHORACIC SURGERY, BIOMED CENTRAL LTD, LO, vol. 8, no. 1, 22 April 2013 (2013-04-22), page 106, XP021145750, ISSN: 1749-8090, DOI: 10.1186/1749-8090-8-106KRAUSE, FriedemannAn der Freiheit 15082377 PenzbergDEROLNY, VinzentKapuzinerstrasse 25a80337 MünchenDEDAYYANI, Farshid58 PlantationIrvine, California 92620USESCHERICH, AchimBueelstrasse 196052 HergiswilCHWEHNL, BirgitWeilheimerstrasse 1581373 MünchenDEHE, YingFallstrasse 40e81369 MünchenDERIEDLINGER, JuliaMangfallweg 1185521 OttobrunnDEHERTH, Felixc/o Thoraxklinik Heidelberg gGmbH Röntgenstrasse 169126 HeidelbergDEMULEY, Thomasc/o Thoraxklinik Heidelberg gGmbH Röntgenstrasse 169126 HeidelbergDERoche Diagnostics GmbH101456586R69898PCEPSandhofer Straße 11668305 MannheimDEDEF. Hoffmann-La Roche AG100120468R69898PCEPGrenzacherstraße 1244070 BaselCHALATBEBGCHCYCZDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRTeschemacher, Andrea101140727Patentanwälte Isenbruck Bösl Hörschler PartG mbB Prinzregentenstraße 6881675 MünchenDEALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTREP201607531320161021enWO201706809720170427201717